Skip to main content
Pharmala Biotech Holdings Inc. logo

Pharmala Biotech Holdings Inc. — Investor Relations & Filings

Ticker · MDMA ISIN · CA71719L1067 CSE Manufacturing
Open in API
Filings indexed 175 across all filing types
Latest filing 2026-04-21 Earnings Release
Country CA Canada
Listing CSE MDMA

About Pharmala Biotech Holdings Inc.

https://pharmala.ca/

Pharmala Biotech Holdings Inc. is a biotechnology company focused on the research, development, manufacturing, and supply of clinical-grade MDMA and novel MDXX class molecules. The company produces LaNeo™ MDMA, an Active Pharmaceutical Ingredient (API) manufactured under Good Manufacturing Practice (GMP) standards, intended for the scientific research community and commercial clinical use in authorized jurisdictions. Pharmala's strategy emphasizes a "regulatory-first" approach, including preclinical research and development of Novel Chemical Entities (NCEs) based on MDXX analogs to enhance safety profiles. The company has established the first legal commercial value chain in North America for GMP LaNeo™ MDMA products and is a primary supplier of MDMA for human use manufactured under GMP guidelines.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release summarizing PharmAla’s Q2 (interim) financial results with key metrics (revenues, net loss, cash flows) and highlights, along with disclosures of stock option grants and a management transition. It provides condensed financial highlights and directs readers to SEDAR+ for the full unaudited interim statements and MD&A. This format—key quarterly results in a press release—is characteristic of an Earnings Release rather than the full Interim Report itself (which would be a detailed report) or a mere publication announcement. Therefore, the correct classification is Earnings Release (ER). Q2 2026
2026-04-21 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a CEO’s Certification of Interim Filings on Form 52-109FV2 under Canadian securities rules, certifying the interim financial report and MD&A for the period ended February 28, 2026. It is neither the full interim report itself nor an earnings release, dividend notice, or capital transaction. It is a statutory certification form included in regulatory filings. No other specific category matches this certification filing, so it falls under the general Regulatory Filings category.
2026-04-21 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion and Analysis – Quarterly Highlights Period Ended February 28, 2026” and contains forward‐looking statements, performance discussion, and business trends commentary. It is an Interim MD&A, a standalone management report explaining the company’s interim results and outlook. This aligns with the “Management Reports” category (Code: MDA).
2026-04-21 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a standard Canadian regulatory certification for interim filings. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like an interim report), should be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial statements or substantive financial data. Q1 2026
2026-04-21 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is Form 52-109FV2, a CEO’s certification of interim filings for a venture issuer under Canadian NI 52-109. It contains no financial statements or MD&A itself but certifies those filings. It is a regulatory compliance form rather than the interim report (IR) or an announcement of report publication (RPA). It best fits the fallback category for miscellaneous regulatory filings (RNS).
2026-04-21 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive set of 'Condensed Interim Consolidated Financial Statements' for PharmAla Biotech Holdings Inc. for the periods ended February 28, 2026 and 2025. It includes detailed financial tables (Statements of Financial Position, Loss and Comprehensive Loss, Cash Flows, and Changes in Shareholders' Equity) and extensive explanatory notes. It is not an announcement or a summary, but the actual interim financial report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2026
2026-04-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.